¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦

ÀÎõÀü¸³¼±¿° Ä¡·á Ãßõ!

ÃßõÇϱâ
ÇÑÀÇ¿ø À̹øÁÖ BEST
 
#ÀÎõÀü¸³¼±¿°, #ÀÎõÀü¸³¼±¿°Ä¡·á, #°£Áú¼º¹æ±¤, #ÀÎõ°£Áú¼º¹æ±¤, #Àü¸³¼±¿°Ä¡·á, #°£Áú¼º¹æ±¤Ä¡·á, #ÀÎõ°£Áú¼º¹æ±¤, #¿¬¼öµ¿Àü¸³¼±¿° ÀÎõÀü¸³¼±¿°,,ÀÎõÀü¸³¼±¿°Ä¡·á,,°£Áú¼º¹æ±¤,,ÀÎõ°£Áú¼º¹æ±¤,,Àü¸³¼±¿°Ä¡·á,,°£Áú¼º¹æ±¤Ä¡·á,,ÀÎõ°£Áú¼º¹æ±¤,,¿¬¼öµ¿Àü¸³¼±¿° ¾È³çÇϼ¼¿ä. ÀÎõÀü¸³¼±¿° ¿¬¼öµ¿ ÇÑÀÇ¿ø ãÀ¸½Ã´Â ºÐµéÀÌ ¸¹À¸½Åµ¥¿ä ÀÎõÀü¸³¼±¿° ¿¬¼öµ¿ Ä¡·á ãÀ¸½Ã´Â ºÐµéÀÌ ¹Ì¿ÃÇÑÀÇ¿ø ÀÎõÁ¡À» ÀÚÁÖ Ã£À¸½Ã´Âµ¥¿ä. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â°£Áú¼º¹æ±¤, Àý¹Ú´¢, ¼ºÀξߴ¢Áõ, ¿©¼ºÀÜ´¢°¨, ¿ÀÁܼÒÅÂ, ¼Ò¾Æ¿ÀÁܼÒÅÂ, ÀÜ´¢°¨Ä¡·á, ¾î¸°ÀÌ¿ÀÁܼÒÅÂ, ¼Òº¯Ç÷´¢, ºó´¢, ¿©Àڹ汤¿°, ¿äµµ¿°, Àü¸³¼±, Àü¸³¼±¿°, ÀÜ´¢, °£Áú¼º¹æ±¤¿°, Áú¿°ÀÜ´¢°¨, ³²ÀÚ¿äµµ¿°, ³²Àڹ汤¿°, °ú¹Î¼º¹æ±¤, ¿ä½Ç±Ý, ÀÜ´¢°¨, ¿äµµÁõÈıº, ¼îº¯ÀÜ´¢°¨, À¯¾Æ¿ÀÁܼÒÅÂµî ´Ù¾çÇÑ ¹®ÀǸ¦ ÁÖ°í °è½Ê´Ï´Ù. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â ´Ù¾çÇÑ È¯ÀںеéÀÌ ³»¿øÇÏ°í °è½Ã¸ç °³Àκ° Áõ»ó°ú üÁú¿¡ µû¶ó °æ±Ù°£¼·ÀúÁÖÆÄ, ÀåħÀü±âÀڱؼú, ¿À°ø¾àħ, µµÀο¿ä¹ý, ¿ªÇÐÄ¡·á, ¾óÀ½¿åÁ¶, »ê»ï¾àħ, º¹Àâ¿îµ¿Ä¡·á, ¹è³óÄ¡·á, ½ÉºÎÈÆÁõ°æ¶ô¾àÂò¿ä¹ý, ±â´ÉÀûÀü±âÀÚ±ØÄ¡·á, ºñ¸¸Ã³¹æ, ÃÊÀ½ÆĽɺο­Ä¡·á, ¼öÄ¡·á, »ê»ïºñ¸¸¾àħ, ÇѹæÀçÈ°, üÁßÁ¶Àý¿µ¾ç±³À°ÆÐÅ°Áö, Ư¼öÃß³ª, °æ±ÙÃß³ª¿ä¹ý, ½ÃÇÁ°Ö, ¸ÂÃãÇÑ¾à µî ÇÕ¸®ÀûÀÌ°í È¿°úÀûÀÎ ¸ÂÃã Ä¡·á¸¦ Á¦°øÇÏ°í ÀÖ½À´Ï´Ù ¹Ì¿ÃÇÑÀÇ¿øÀº Àü±¹ 20¿©°³ ÁöÁ¡¿¡¼­ Áø·áÁßÀÌ¸ç ºÎ»ê ºÏ±¸ ¸¸´öµ¿, ÀüºÏ ÀÍ»ê½Ã ³¶»ê¸é, °æºÏ ±èõ½Ã ±¸¼º¸é, °æºÏ °æÁֽà ½Ã·¡µ¿, ºÎ»ê Áß±¸ º¸¼öµ¿3°¡, ÀÎõ ¿ËÁø±º ´ëû¸é, °­¿ø °­¸ª½Ã ÀӴ絿, ÀüºÏ ÀÍ»ê½Ã ÆȺÀµ¿, ÃæºÏ ÃæÁֽà ÁöÇöµ¿, °æ±â ¾È¼º½Ã ÀÎÁöµ¿, Àü³² ¸ñÆ÷½Ã Áßµ¿1°¡, °æ³² °í¼º±º µ¿Çظé, Àü³² ³ªÁֽà ûµ¿, Àü³² ¿µ±¤±º ¿°»ê¸é, Á¦ÁÖ ¼­±ÍÆ÷½Ã ¼­±Íµ¿, °­¿ø Źé½Ã Àû°¢µ¿, °æ±â ¼º³²½Ã ºÐ´ç±¸ ¹éÇöµ¿, °æ³² â¿ø½Ã ÁøÇر¸ Åë½Åµ¿, °æºÏ °æÁֽà Ȳ³²µ¿, Àü³² ¸ñÆ÷½Ã À²µµµ¿, Àü³² ¿©¼ö½Ã ¿©¼ö¿ìü±¹»ç¼­ÇÔ, Ãæ³² ¼­Ãµ±º ½ÃÃʸé, ºÎ»ê ºÏ±¸ È­¸í3µ¿, °æºÏ ¿µ¾ç±º ¼®º¸¸é, Àü³² ´ã¾ç±º ¹«Á¤¸é, °æ±â ºÎõ½Ã ¼Ò»ç±¸ ¹ü¹Úµ¿, °æºÏ ¾Èµ¿½Ã ¸ñ¼ºµ¿, °æ±â ¼º³²½Ã ¼öÁ¤±¸ ¼öÁøµ¿, °æºÏ ¿µ´ö±º ¿µ´öÀ¾, ÀüºÏ ÀüÁֽà ´öÁø±¸ ¿©Àǵ¿, µî ´Ù¾çÇÑ Áö¿ª Áֹε鲲¼­ ³»¿øÇÏ°í °è½Ê´Ï´Ù ÀÎõÀü¸³¼±¿°Ä¡·á ãÀ¸½Ã´Â ¿ëÀ¯µµ, ¼Û¸²µ¿, ¼Ûµµ±¹Á¦µµ½Ã, ÀÎõ¼­±¸, µ¿ÀÎõ, ¿¬¼ö±¸, °ü±³µ¿, ¸¶µµ¸é, ¿î¼­µ¿, ÀÎõÁÖ¾È, ¼Ûµµ½Åµµ½Ã, ±¸¿ùµ¿, ¿¬Èñµ¿, °¡Áµ¿, ½ÃÈ­, Áß±¸, Áßµ¿, µ¿±¸, ³íÇö°íÀܵ¿, °£¼®µ¿, ¸Å¼Û¸é, ¸¸¼öµ¿, ´ëºÎµµ, ¼±Çе¿, µ¿Ãᵿ, ¼Û»ê¸é, °è»êµ¿, ¿î³²µ¿, °Ë¾Ï, ¿¬¼öµ¿, °¡Á¤µ¿, Á־ȿª, ³²±¸, »óµ¿, ÇÐÀ͵¿ µî ÀÎõ Áö¿ª Áֹε鲲¼­ ¹Ì¿ÃÇÑÀÇ¿øÀÎõÁ¡À» ¹æ¹®ÇÏ°í °è½Ê´Ï´Ù. ´õ »ìÆ캸±â 1. Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 2014; 46:275. 2. Cigolle CT, Langa KM, Kabeto MU, et al. Geriatric conditions and disability: the Health and Retirement Study. Ann Intern Med 2007; 147:156. 3. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101:1388. 4. Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008; 112:1311. 5. Chapple CR, Nazir J, Hakimi Z, et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol 2017; 72:389. 6. Pearce MM, Zilliox MJ, Rosenfeld AB, et al. The female urinary microbiome in urgency urinary incontinence. Am J Obstet Gynecol 2015; 213:347.e1. 7. Sebastianelli A, Russo GI, Kaplan SA, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol 2018; 25:196. 8. Offermans MP, Du Moulin MF, Hamers JP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn 2009; 28:288. 9. Effective Health Care Program. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Agency for Healthcare Research Quality 2012. Available at: http://effectivehealthcare.ahrq.gov/ehc/products/169/1021/CER36_Urinary-Incontinence_execsumm.pdf (Accessed on November 19, 2012). 10. Brown JS, Sawaya G, Thom DH, Grady D. Hysterectomy and urinary incontinence: a systematic review. Lancet 2000; 356:535.
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ÀÎõÀü¸³¼±¿° Ä¡·á Ãßõ!""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀÎõ¸ð°ø°¢È­Áõ Ä¡·á µµ¿òÀ»
´ÙÀ½±Û ¹®Çе¿ÇÑÀÇ¿ø ¿Á·Ãµ¿ ¿ëÇöµ¿ ÁÖ¸»Áø·á ¾î¶² Ä¡·á¸¦?
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
872 ½ÅÃÌ´ÙÀ̾îÆ®ÇÑ¾à °Ç°­ÇÏ°Ô °ü¸®¸¦ ÇÏ°í ¿øÇÏ´Â ¸öÀ» ¸¸µé±â 3 1,060 2022-01-19
871 ¿ï»ê´ÙÀ̾îÆ®ÇÑÀÇ¿ø ÀÚ¿¬°úÇÑÀÇ¿ø¿¡¼­ ¼ö¿ùÇÏ°Ô Ã¼Áß °¨·® 1 1,162 2022-01-19
870 ºÐ´ç´ÙÀ̾îÆ®ÇÑÀÇ¿ø 1 1,341 2022-01-19
869 õ¾È´ÙÀ̾îÆ®ÇÑÀÇ¿ø ¿ÃÇØ »ì »©±â ¼º°øÇÏ°í ½ÍÀ¸¸é ÀÚ¿¬°úÇÑÀÇ¿ø¿¡¼­! 1 1,088 2022-01-19
868 ÀÏ»ê´ÙÀ̾îÆ®ÇÑÀÇ¿ø °èȹÀûÀÌ°í ¼øÁ¶·Î¿î üÁß °¨·® 1 790 2022-01-19
867 ÀºÆò¿¬½Å³»´ÙÀ̾îÆ®ÇÑÀÇ¿ø¿¡¼­ °Ç°­ÇÏ°Ô °ü¸®¸¦ ÇØ¿ä 1 770 2022-01-18
866 ¼ö¿ø´ÙÀ̾îÆ®ÇÑÀÇ¿ø ³ª¿¡°Ô ¸Â´Â ¹æ½ÄÀ¸·Î ¿Ã¹Ù¸£°Ô 1 802 2022-01-18
865 ûÁÖ´ÙÀ̾îÆ®ÇÑÀÇ¿ø °Ç°­ÇÏ°Ô °ü¸®¸¦ ÇغÁ¿ä 0 574 2022-01-18
864 µ¿Åº´ÙÀ̾îÆ®ÇÑÀÇ¿ø ¸¸Á·°¨ ³ôÀº °ü¸® 2 733 2022-01-18
863 ÇØ¿î´ë´ÙÀ̾îÆ®ÇÑÀÇ¿ø ÀÚ¿¬°úÇÑÀÇ¿ø¿¡¼­ ÀÌ»Û ¸öÀ» ¸¸µé¾î¿ä 1 608 2022-01-18
862 ÆòÃÌ´ÙÀ̾îÆ®ÇÑÀÇ¿ø ÀÚ¿¬°úÇÑÀÇ¿ø¿¡¼­ üÁú¿¡ ¸Â°Ô ÁøÇàÇϼ¼¿ä 2 546 2022-01-18
861 ¸ñµ¿´ÙÀ̾îÆ®ÇÑÀÇ¿ø °Ç°­ÇÑ Ã¼Áß °ü¸® ¹æ¹ýÀ» ¼±Åà 1 598 2022-01-18
860 ¸íµ¿´ÙÀ̾îÆ®ÇÑÀÇ¿ø °Ç°­ÇÑ Ã¼Áß °ü¸® ÇÒ ¼ö ÀÖ¾î¿ä 1 485 2022-01-18
859 ¼­¸é´ÙÀ̾îÆ®ÇÑÀÇ¿ø ÀÚ¿¬°úÇÑÀÇ¿ø°ú ÇÔ²² °ü¸®¸¦ ÇغÁ¿ä 1 761 2022-01-18
858 ±¤ÁÖ´ÙÀ̾îÆ®ÇÑÀÇ¿ø ÀÚ¿¬°úÇÑÀÇ¿ø¿¡¼­ È¿À²ÀûÀ¸·Î üÁß °ü¸® ÇØ º¸¼¼¿ä 2 781 2022-01-18
857 °­³²´ÙÀ̾îÆ®ÇÑÀÇ¿ø °Ç°­°ú üÁß °ü¸® ¸ðµÎ ÀâÀ» ¼ö ÀÖ¾î¿ä 2 445 2022-01-18
856 ¼öÇÑÀÇ¿ø °Ü¿ï¹æÇÐ ¿©µå¸§°ü¸® ÇÒÀÎ À̺¥Æ® 0 1,072 2021-11-29
855 Àϻ긮»ùÇÑÀÇ¿ø 11¿ùÀ̺¥Æ®¼Ò½Ä 0 747 2021-10-26
854 Àá½Ç»õ³»¿ª ÇÑÀÇ¿ø ¸¶À½¸ð¾ÆÇÑÀÇ¿ø 10¿ùÁø·á¾È³» 0 607 2021-09-29
853 ¸¶»ê´ÙÀ̾îÆ® °æÈñÀÚ¿¬ÇÑÀÇ¿ø 10¿ùÀ̺¥Æ® 0 964 2021-09-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷